# A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)

> **NCT03772288** · PHASE1 · WITHDRAWN · sponsor: **Calithera Biosciences, Inc**

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** TAK-659
- **DRUG:** NKTR-214

## Key facts

- **NCT ID:** NCT03772288
- **Lead sponsor:** Calithera Biosciences, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-04-03
- **Primary completion:** 2021-11-10
- **Final completion:** 2021-11-17
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business Decision: No Safety or Efficacy Concerns
- **Last updated:** 2023-02-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03772288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03772288, "A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03772288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*